@entity4677 in @entity1 and adolescents with XXXX and @entity306 .

@entity1 @entity4677 @entity410 @entity302 @entity306
AIM: To monitor the effect of adding @entity4677 in paediatric @entity1 with @entity306 and @entity302 . METHODS: A case series of eight @entity1 with @entity306 whose focal @entity410 were not adequately controlled by their current anticonvulsants were monitored after @entity4677 was added to their medications. If there was a 50% reduction in @entity410 frequency, then the other anticonvulsants were discontinued. Prolonged follow-up occurred for a minimum of 2 years. RESULTS: There were seven males and one female whose ages ranged from 4 years to 17 years. All had focal onset @entity410 , while seven also had secondarily generalised tonic @entity410 . @entity4677 resulted in at least a 50% reduction in @entity410 frequency in seven, with no change in one. Three were able to wean successfully to monotherapy and remained @entity410 free for over 2 years. They had a prior history of infrequent @entity410 , one to six per year. Those who continued to require multiple anticonvulsants had a prior history of more frequent @entity410 , 6-50/year. @entity4677 was well tolerated, and none ceased this because of side effects. CONCLUSION: @entity4677 is likely to be an effective anticonvulsant in @entity1 and adolescents with @entity306 and infrequent but persistent focal @entity410 .
